Breast Cancer Post Market Monitoring of Drugs & Procurement Strategies

Abstract

Breast cancer represents a formidable global health challenge, necessitating continual advancements in treatment modalities and healthcare delivery. This research paper explores the pivotal intersection of post-market monitoring of breast cancer drugs and strategic procurement strategies, aiming to optimize patient outcomes while ensuring accessibility and affordability. Beginning with an overview of the current landscape, this paper investigates the methodologies and regulatory frameworks governing post-market monitoring breast cancer drugs. It scrutinizes the strengths and limitations of existing surveillance mechanisms, including spontaneous reporting systems and real-world evidence generation, and examines emerging trends such as Pharmacovigilance in digital health platforms. This paper delves into the complexities of drug procurement, analyzing various strategies employed by healthcare systems and stakeholders to enhance accessibility and affordability